RIXS STUDIES OF PLATINUM COMPLEXES FOR CANCER THERAPY

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 顺铂（cis-[PtCl 2（NH3）2]）是最广泛使用的抗癌药物之一，已被证明是卵巢癌、睾丸癌和宫颈癌的有效治疗方法。 然而，尽管它在治疗几种类型的癌症方面非常有效;顺铂也是有毒的，并且有许多类型的癌症不能有效靶向。 为了改善治疗，许多研究集中在合成不同类型的Pt络合物，其具有降低的毒性、增加的活性和口服给药的能力。 许多这些小的化合物可以结晶和衍射研究的特点。 然而，为了理解这些复合物的机理，对溶液结构的理解至关重要。 最近，我们已经使用Pt L3-edge XAS来表征Pt抗癌剂的固体和溶液结构，包括Pt-Streptidine。 未来的研究将包括检查癌细胞内的Pt协调环境。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Cisplatin (cis-[PtCl2(NH3)2])) is one of the most widely used anticancer drugs and has been shown to be an effective treatment for ovarian, testicular and cervical cancers. However, despite the fact that it is highly effective in treating several types of cancer; cisplatin is also toxic and there are many types of cancer that it does not effectively target. In an effort to improve treatment, much research has focused on synthesizing different type of Pt complexes with reduced toxicity, increased activity, and the ability to be administered orally. Many of these small chemical compounds can be crystallized and characterized by diffraction studies. However, in order to understand the mechanism of these complexes, an understanding of the solution structure is vital. Recently we have used Pt L3-edge XAS to characterize solid and solution structures of Pt anticancer agents, including Pt-Streptidine. Future studies will include examination of the Pt coordination environment within cancerous cells.